Dr Philipp Ivanyi

Go Back

Medical Oncologist

  • Hannover Medical School
  • location Germany

Dr Ivanyi is the Assistant Medical Director Hematology, Oncology, Hemostasis, Stem Cell Transplantation (Palliative Care) at the Hanover Medical School. He is also Head of the Clinical Trial Unit for Medical Oncology

Dr Ivanyi also serves as:

·
Steering Committee and Spokesman, Immune Cooperative Oncology Group, Comporehensive Cancer Center, Claudia von Schelling Center (CCC-H)
·
Board Member, Clinical Trial Steering Committee, CCC-H
·
Spokesman Interdisciplinary Working Group Kidney Cancer, Germany Cancer Society (IAGN-DKG)

His research interests include clinical and experimental Research in Urogenital Cancer, Head and Neck Cancer, Sarcoma, Rare Cancers, Targeted Therapies. He has >80 SCI Publication and has a depth of experience in >50 Clinical Trials Phase I – IV (PI and Country Lead).

Dr Philipp Ivanyi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AIM, AIO, Apogepha, Astella, Astra Zeneca, Bayer, BMS, ClinSol, Deciphera, Deutsche Gesellschaft für Thoraxchirurgie, DKG-Onkoweb, EISAI, EMD-Serono, EUSA, FoFM, GSK, Id-Institut, Ipsen (Europe), Lilly, MedKom, Metaplan, MedWiss, Merck Serono (Global), MSD, MTE-Academy, New Concept Oncology, Niedersächsische Krebsgesellschaft, Novartis, Onkowissen-tv.de, Pharma Mare, Pfizer, Roche, Schmitz-Communikation, Solution Academy,Stiftung Immunonkologie, StreamedUP!, ThinkWired!, Vivantis and Wilhelm Sander Stiftung.

Programmes developed by Dr Philipp Ivanyi

conference-update Conference update
Oncology 
Precision Oncology Update From ESMO 2023

How will the latest data impact clinical practice?

Experts
Dr Philipp Ivanyi
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Oct 2023

Educational programme supported by an Independent Educational Grant from Bayer.
e-learning Interactive e-learning

Module

2

of 3

module
Oncology 
Patient case reports: from diagnosis to treatment of TRK-fusion positive cancer

Prof. David Hong: Lung cancer, sarcoma and GI cancer

Experts
Dr Philipp Ivanyi, Assoc. Prof. Caterina Marchiò, Prof. David Hong
  • clock 15 MIN
  • calendar Aug 2022

Educational programme supported by an Independent Educational Grant from Bayer
e-learning Interactive e-learning

Module

3

of 3

module
Oncology 
Patient case reports: from diagnosis to treatment of TRK-fusion positive cancer

Dr Philipp Ivanyi: A thyroid cancer case

Experts
Dr Philipp Ivanyi, Assoc. Prof. Caterina Marchiò, Prof. David Hong
  • clock 20 MIN
  • calendar Aug 2022

Educational programme supported by an Independent Educational Grant from Bayer
e-learning Interactive e-learning

Module

1

of 3

module
Oncology 
Patient case reports: from diagnosis to treatment of TRK-fusion positive cancer

Assoc. Prof. Caterina Marchio: A lung cancer case

Experts
Dr Philipp Ivanyi, Assoc. Prof. Caterina Marchiò, Prof. David Hong
  • download Downloadable
    Resources
  • clock 15 MIN
  • calendar Aug 2022

Educational programme supported by an Independent Educational Grant from Bayer